First Comprehensive Gene Map of the Human Brain Developed
|
By LabMedica International staff writers Posted on 26 Apr 2011 |
A new human brain atlas reveals more than 90% similarity among humans, and details genes at work throughout the brain to further scientific research and medical outcomes.
The Allen Institute for Brain Science (Seattle, WA, USA) has released the world's first anatomically and genomically comprehensive human brain map, a previously improbable endeavor made possible through leading-edge technology and more than four years of demanding studies and documentation. The mappings are the foundation for the Allen Human Brain Atlas, an online public resource developed to advance the Institute's goal to accelerate understanding of how the human brain works and fuel new discovery among the global research community.
In developing the Allen Human Brain Atlas, the Allen Institute has now characterized and mapped the biochemistry of two normal adult human brains, providing opportunities for scientists to study the brain with new detail and accuracy. The data reveal a remarkable 94% similarity between human brains, establishing strong patterns as a critical foundation for translational and clinical research. Moreover, data analysis from the two human brains indicate that at least 82% of all human genes are expressed in the brain, highlighting its great complexity while also providing an essential genetic blueprint to understand brain functionality better and fuel research in neurologic disease and other brain disorders.
"Until now, a definitive map of the human brain, at this level of detail, simply hasn't existed,” said Allan Jones, PhD, chief executive officer of the Allen Institute for Brain Science. "The Allen Human Brain Atlas provides never-before-seen views into our most complex and most important organ. Understanding how our genes are used in our brains will help scientists and the medical community better understand and discover new treatments for the full spectrum of brain diseases and disorders, from mental illness and drug addiction, to Alzheimer's and Parkinson's diseases, multiple sclerosis, autism, and more.”
Similar to a high-powered, multifunctional GPS (global positioning system) navigation system, the Allen Human Brain Atlas identifies 1,000 anatomic sites in the human brain, underscored by more than 100 million data points that indicate the particular gene expression and underlying biochemistry of each site. Scientists can utilize the Allen Human Brain Atlas to explore the human brain and identify how disease and trauma, including physical brain injuries and mental health disorders, affect specific areas of the brain. This resource makes it possible to pinpoint where a particular drug acts anatomically in the brain, to ultimately better control the successful outcome of numerous therapies.
"The Allen Institute is a powerful force in modern science,” said Dr. Edward Jones, neuroscientist at the University of California, Davis. "They've applied an industrialized approach and high-output technology to accomplish what no other lab has ever done. The original data produced for the mouse brain revolutionized neuroscience and now the Allen Human Brain Atlas delivers extremely rare and essential information that most researchers could not otherwise access. They are truly paving the way for the future of research."
The Allen Human Brain Atlas is free and available to scientists, physicians, and the education community as an online public resource (please see Related Links below).
Previously, as its inaugural initiative, the Allen Institute for Brain Science completed mappings of the adult mouse brain in 2006, similarly making the data available free to scientists. Overall, those data have led to a number of significant research advances worldwide, including the publishing of over 500 peer-reviewed papers citing the Allen Mouse Brain Atlas to support research conclusions.
A significant feature of the Atlas that makes it a powerful research tool is that it fully integrates several different kinds of data across different scales of brain exploration. Data incorporated into the Atlas include magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), as well as histology and gene expression data derived from both microarray and in-situ hybridization (ISH) approaches.
Users of the Allen Human Brain Atlas comprise a diverse range of biomedical researchers--primarily neuroscientists--throughout the world. They include scientists who study the human brain itself, as well as those working in mouse and other model systems, providing a rare and important opportunity for them to probe the relevance of the findings to humans. Some 4,000 unique visitors are now accessing the new Atlas each month.
It is anticipated that the Allen Human Brain Atlas will be used in small and large-scale applications to examine diseases and disorders, such as obesity, Parkinson's disease, autism, schizophrenia, Alzheimer's disease, and multiple sclerosis--as well as those exploring how the healthy brain works.
The Allen Institute for Brain Science will continue to expand the Allen Human Brain Atlas in the coming years, with new data from additional brains, as well as enhanced tools for searching, analyzing, and viewing the data.
The Allen Institute for Brain Science is a medical research organization focused on accelerating understanding of the human brain by driving discovery for the broader scientific community.
Related Links:
Allen Institute for Brain Science
Allen Human Brain Atlas
The Allen Institute for Brain Science (Seattle, WA, USA) has released the world's first anatomically and genomically comprehensive human brain map, a previously improbable endeavor made possible through leading-edge technology and more than four years of demanding studies and documentation. The mappings are the foundation for the Allen Human Brain Atlas, an online public resource developed to advance the Institute's goal to accelerate understanding of how the human brain works and fuel new discovery among the global research community.
In developing the Allen Human Brain Atlas, the Allen Institute has now characterized and mapped the biochemistry of two normal adult human brains, providing opportunities for scientists to study the brain with new detail and accuracy. The data reveal a remarkable 94% similarity between human brains, establishing strong patterns as a critical foundation for translational and clinical research. Moreover, data analysis from the two human brains indicate that at least 82% of all human genes are expressed in the brain, highlighting its great complexity while also providing an essential genetic blueprint to understand brain functionality better and fuel research in neurologic disease and other brain disorders.
"Until now, a definitive map of the human brain, at this level of detail, simply hasn't existed,” said Allan Jones, PhD, chief executive officer of the Allen Institute for Brain Science. "The Allen Human Brain Atlas provides never-before-seen views into our most complex and most important organ. Understanding how our genes are used in our brains will help scientists and the medical community better understand and discover new treatments for the full spectrum of brain diseases and disorders, from mental illness and drug addiction, to Alzheimer's and Parkinson's diseases, multiple sclerosis, autism, and more.”
Similar to a high-powered, multifunctional GPS (global positioning system) navigation system, the Allen Human Brain Atlas identifies 1,000 anatomic sites in the human brain, underscored by more than 100 million data points that indicate the particular gene expression and underlying biochemistry of each site. Scientists can utilize the Allen Human Brain Atlas to explore the human brain and identify how disease and trauma, including physical brain injuries and mental health disorders, affect specific areas of the brain. This resource makes it possible to pinpoint where a particular drug acts anatomically in the brain, to ultimately better control the successful outcome of numerous therapies.
"The Allen Institute is a powerful force in modern science,” said Dr. Edward Jones, neuroscientist at the University of California, Davis. "They've applied an industrialized approach and high-output technology to accomplish what no other lab has ever done. The original data produced for the mouse brain revolutionized neuroscience and now the Allen Human Brain Atlas delivers extremely rare and essential information that most researchers could not otherwise access. They are truly paving the way for the future of research."
The Allen Human Brain Atlas is free and available to scientists, physicians, and the education community as an online public resource (please see Related Links below).
Previously, as its inaugural initiative, the Allen Institute for Brain Science completed mappings of the adult mouse brain in 2006, similarly making the data available free to scientists. Overall, those data have led to a number of significant research advances worldwide, including the publishing of over 500 peer-reviewed papers citing the Allen Mouse Brain Atlas to support research conclusions.
A significant feature of the Atlas that makes it a powerful research tool is that it fully integrates several different kinds of data across different scales of brain exploration. Data incorporated into the Atlas include magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), as well as histology and gene expression data derived from both microarray and in-situ hybridization (ISH) approaches.
Users of the Allen Human Brain Atlas comprise a diverse range of biomedical researchers--primarily neuroscientists--throughout the world. They include scientists who study the human brain itself, as well as those working in mouse and other model systems, providing a rare and important opportunity for them to probe the relevance of the findings to humans. Some 4,000 unique visitors are now accessing the new Atlas each month.
It is anticipated that the Allen Human Brain Atlas will be used in small and large-scale applications to examine diseases and disorders, such as obesity, Parkinson's disease, autism, schizophrenia, Alzheimer's disease, and multiple sclerosis--as well as those exploring how the healthy brain works.
The Allen Institute for Brain Science will continue to expand the Allen Human Brain Atlas in the coming years, with new data from additional brains, as well as enhanced tools for searching, analyzing, and viewing the data.
The Allen Institute for Brain Science is a medical research organization focused on accelerating understanding of the human brain by driving discovery for the broader scientific community.
Related Links:
Allen Institute for Brain Science
Allen Human Brain Atlas
Latest BioResearch News
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
Channels
Clinical Chemistry
view channel
Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more
Blood-Based Alzheimer’s Testing Platform Offers Rapid Results
Accurate identification of Alzheimer’s disease pathology often relies on cerebrospinal fluid analysis or positron emission tomography, which can be invasive, costly, and not widely accessible.... Read more
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreMolecular Diagnostics
view channel
AI Reasoning Model Generates Diagnostic Leads for Unresolved Rare Disease Cases
Rare genetic diseases often leave families without definitive answers, even after genome sequencing and expert review. As scientific evidence evolves and clinical data remain fragmented across systems,... Read more
Point-of-Care Molecular Test Detects Group A Strep in Minutes
Group A Streptococcus is a leading bacterial cause of acute pharyngitis and a common reason for outpatient visits, accounting for millions of healthcare encounters each year. Because symptoms of bacterial... Read more
Genetic Testing and Surveillance Cuts Costs and Improves Survival in Li-Fraumeni Syndrome
Inherited cancer predisposition syndromes such as Li-Fraumeni syndrome (LFS) can lead to diverse, early-onset tumors and require intensive, lifelong surveillance. Balancing timely identification with sustainable... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. For immunotherapy evaluation, the precise sequence... Read more
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreMicrobiology
view channel
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more








